Publications by authors named "Fritz Offner"

Claim this Profile
C
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment: Process evaluation study of the CODE intervention in doctors and nurses working in ten acute hospital wards.
Ruth Piers, Let Dillen, Katrijn Goethals, An Lievrouw, Karen Versluys, Fritz Offner

PLoS One· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
Arnon P Kater, Ann Janssens, Herbert Eradat, Fritz Offner, Jose D Sandoval-Sus

Lancet Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Jan A Burger, Paul M Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Fritz Offner

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy.
Bert Luyckx, Maaike Van Trimpont, Fien Declerck, Eleni Staessens, Annick Verhee, Fritz Offner

Pharmacol Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publisher Correction: Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial.
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, Ine Moors, Fritz Offner

Intensive Care Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
Tycel Jovelle Phillips, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Fritz Offner

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Coaching doctors to improve ethical decision-making in adult hospitalized patients potentially receiving excessive treatment. The CODE stepped-wedge cluster randomized controlled trial.
Dominique D Benoit, Aglaja De Pauw, Celine Jacobs, Ine Moors, Fritz Offner

Intensive Care Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Knocking Out CD70 Rescues CD70-Specific NanoCAR T Cells from Antigen-Induced Exhaustion.
Stijn De Munter, Juliane L Buhl, Laurenz De Cock, Alexander Van Parys, Willem Daneels, Fritz Offner

Cancer Immunol Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.
Philippe Decruyenaere, Willem Daneels, Annelien Morlion, Kimberly Verniers, Jasper Anckaert, Fritz Offner

Int J Mol Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Fritz Offner

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma.
Willem Daneels, Alexander Van Parys, Leander Huyghe, Elke Rogge, Steffi De Rouck, Fritz Offner

Exp Hematol Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Martin Dreyling, Nathan Hale Fowler, Michael Dickinson, Joaquin Martinez-Lopez, Arne Kolstad, Fritz Offner

Blood· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.
Thomas Van Den Berghe, Bert Verberckmoes, Nicolas Kint, Steven Wallaert, Nicolas De Vos, Fritz Offner

Insights Imaging· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial.
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner

EJHaem· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.
Philippe Decruyenaere, Edoardo Giuili, Kimberly Verniers, Jasper Anckaert, Katrien De Grove, Fritz Offner

Front Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
Dorien Clarisse, Stefan Prekovic, Philip Vlummens, Eleni Staessens, Karlien Van Wesemael, Fritz Offner

Cell Mol Life Sci· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma.
Torben Plesner, Simon J Harrison, Hang Quach, Cindy Lee, Adam Bryant, Fritz Offner

Clin Hematol Int· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The iR regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study.
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, Jia Ruan, Kirit M Ardeshna, Fritz Offner

EClinicalMedicine· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA Extraction Method Impacts Quality Metrics and Sequencing Results in Formalin-Fixed, Paraffin-Embedded Tissue Samples.
Philippe Decruyenaere, Kimberly Verniers, Franco Poma-Soto, Jo Van Dorpe, Fritz Offner

Lab Invest· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Fritz Offner

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.
Ann Janssens, Zwi N Berneman, Fritz Offner, Sylvia Snauwaert, Philippe Mineur

Clin Hematol Int· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Michael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, Emmanuel Bachy, Paolo Corradini, Fritz Offner

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.
Philip Vlummens, Stefaan Verhulst, Kim De Veirman, Anke Maes, Eline Menu, Fritz Offner

Front Cell Dev Biol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmenting THerapeutic Effectiveness Through Novel Analytics (ATHENA) - A Public and Private Partnership Project Funded by the Flemish Government (VLAIO).
Ploingarm Petsophonsakul, Ashkan Pirmani, Edward De Brouwer, Murat Akand, Wouter Botermans, Fritz Offner

Stud Health Technol Inform· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.
Daniela Drandi, Philippe Decruyenaere, Martina Ferrante, Fritz Offner, Jo Vandesompele

Diagnostics (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis